EP Patent

EP1470116A4 — Preparation of orlistat and orlistat crystalline forms

Assigned to Teva Pharmaceutical Works PLC · Expires 2005-04-06 · 21y expired

What this patent protects

The present invention is directed to a process of converting lipstatin to orlistat by catalytic hydrogenation. The present invention further discloses novel crystalline solid orlistat forms, designated form I and form II methods for their preparation.

USPTO Abstract

The present invention is directed to a process of converting lipstatin to orlistat by catalytic hydrogenation. The present invention further discloses novel crystalline solid orlistat forms, designated form I and form II methods for their preparation.

Drugs covered by this patent

Patent Metadata

Patent number
EP1470116A4
Jurisdiction
EP
Classification
—
Expires
2005-04-06
Drug substance claim
No
Drug product claim
No
Assignee
Teva Pharmaceutical Works PLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.